![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/18/2900827/0/en/EY-Announces-Scott-Struthers-Ph-D-CEO-and-Founder-of-Crinetics-Pharmaceuticals-as-an-Entrepreneur-Of-The-Year-2024-Pacific-Southwest-Award-Winner.html
https://www.globenewswire.com/news-release/2024/06/10/2896431/0/en/Crinetics-Pharmaceuticals-Announces-June-2024-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/03/2892445/0/en/Crinetics-Announces-Positive-Initial-Findings-at-ENDO-2024-for-Atumelnant-in-Two-Ongoing-Open-Label-Studies-for-the-Treatment-of-Congenital-Adrenal-Hyperplasia-CAH-and-ACTH-Depende.html
https://www.globenewswire.com/news-release/2024/06/03/2892444/0/en/Crinetics-Presents-New-Data-at-ENDO-2024-that-Increases-Body-of-Evidence-Positioning-Once-Daily-Oral-Paltusotine-as-Potential-First-Choice-Treatment-Option-for-Acromegaly.html
https://www.globenewswire.com/news-release/2024/05/30/2891124/0/en/Crinetics-Pharmaceuticals-Appoints-Robert-M-Cuddihy-M-D-as-Senior-Vice-President-of-Medical-Affairs.html
https://endpts.com/crinetics-stock-jumps-following-promising-ph2-data-in-4-patients-with-rare-genetic-disorder/
https://www.globenewswire.com/news-release/2024/05/22/2886415/0/en/Crinetics-Pharmaceuticals-Announces-Early-Release-of-ENDO-2024-Late-Breaking-Abstracts.html
https://www.globenewswire.com/news-release/2024/05/10/2879864/0/en/Crinetics-Pharmaceuticals-Announces-May-2024-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/09/2879152/0/en/Crinetics-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/08/2878214/0/en/Crinetics-Pharmaceuticals-to-Present-Advancements-from-Atumelnant-CRN04894-and-Paltusotine-Development-Programs-at-ENDO-2024.html